Reason why melanoma therapy Zelboraf failed to be registered for insurance benefit

A Roche Korea’s metastatic melanoma treatment ‘Zelboraf(vemurafenib)’ is a drug which still has not been registered in the drug insurance benefit list for more than 4 years after acquiring commercialization approval in Korea. The company made two attempts through the general registration process and using the ‘exemption of turning in economic evaluation data’ system respectively, but failed on ...